COLET研究:cobimetinib联合化疗±atezolizumab一线治疗局部晚期或转移性三阴性乳腺癌的II期随机试验主要分析
COLET是一项三队列II期研究,评估cobimetinib联合化疗±atezolizumab一线治疗局部晚期或转移性TNBC。队列I中cobimetinib联合紫杉醇相比安慰剂联合紫杉醇,中位PFS为5.5个月 vs 3.8个月(HR 0.73,95%CI 0.43-1.24,P=0.25),ORR为38.3% vs 20.9%。结论认为加用cobimetinib未显著提高PFS或ORR,但观察到数值上增加趋势。
要点
- cobimetinib联合紫杉醇未显著改善PFS(HR 0.73,P=0.25)。
- 队列I的ORR在cobimetinib组为38.3%,安慰剂组为20.9%。
- cobimetinib联合atezolizumab及紫杉烷的ORR分别为34.4%和29.0%。
核心结论
- cobimetinib加入紫杉醇未导致PFS或ORR的统计学显著增加,但观察到非显著的数值增加趋势。
- cobimetinib联合atezolizumab和紫杉烷似乎未增加ORR。
- 结果提示MEK抑制剂、化疗和免疫治疗联合在该难治人群中可能具有活性。
研究设计与样本
- COLET是一项三队列II期随机研究,纳入≥18岁局部晚期或转移性TNBC患者。
- 队列I随机1:1接受cobimetinib(60 mg,每28天周期第3-23天)或安慰剂,联合紫杉醇(80 mg/m2,第1、8、15天)。
- 队列II和III随机1:1接受cobimetinib联合atezolizumab(840 mg,第1和15天)及紫杉醇(队列II)或白蛋白紫杉醇(队列III,100 mg/m2,第1、8、15天)。
- 主要终点为队列I的研究者评估PFS和队列II/III的确认ORR,同时评估安全性和耐受性。
主要发现
- 队列I扩展阶段中,cobimetinib/紫杉醇组中位PFS为5.5个月,安慰剂/紫杉醇组为3.8个月(HR 0.73;95%CI 0.43-1.24;P=0.25)。
- 队列I中cobimetinib/紫杉醇组ORR为38.3%(95%CI 24.40-52.20),安慰剂/紫杉醇组为20.9%(95%CI 8.77-33.09)。
- 队列II和III的ORR分别为34.4%(95%CI 18.57-53.19)和29.0%(95%CI 14.22-48.04)。
- 所有队列中最常见的≥3级不良事件为腹泻。
临床怎么用
- 对于局部晚期或转移性TNBC,一线cobimetinib联合紫杉醇未显示显著PFS获益,需谨慎评估联合策略。
- cobimetinib联合atezolizumab及紫杉烷的ORR未见明显提高,不支持该组合作为优选方案。
- 治疗期间需重点监测腹泻等≥3级不良事件。
局限性
- 本研究为II期随机试验,样本量有限,统计效力可能不足以检测微小差异。
- PFS结果未达到统计学显著性,仅为数值趋势。
- 原文未报告总生存期数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Resistance to standard chemotherapy in metastatic triple-negative breast cancer (mTNBC) is associated with upregulation of the mitogen-activated protein kinase (MAPK) pathway. Cobimetinib, an MAPK/extracellular signal-regulated kinase (MEK) inhibitor, may increase sensitivity to taxanes and programmed death-ligand 1 inhibitors. COLET is a three-cohort phase II study evaluating first-line cobimetinib plus chemotherapy, with or without atezolizumab, in patients with locally advanced or mTNBC. PATIENTS AND METHODS: Patients were ≥18 years with locally advanced or mTNBC. Following a safety run-in, patients in cohort I were randomized 1:1 to cobimetinib (60 mg, D3-D23 of each 28-day cycle) or placebo, plus paclitaxel (80 mg/m2, D1, 8, and 15). Additional patients were randomized (1:1) to cohort II or III to receive cobimetinib plus atezolizumab (840 mg, D1 and D15) and either paclitaxel (cohort II) or nab-paclitaxel [cohort III (100 mg/m2, D1, D8, and D15)]. Primary endpoints were investigator-assessed progression-free survival (PFS) (cohort I) and confirmed objective response rate (ORR) (cohorts II/III). Safety and tolerability were also assessed. RESULTS: In the expansion stages, median PFS was 5.5 months for cobimetinib/paclitaxel versus 3.8 months for placebo/paclitaxel in cohort I [hazard ratio 0.73; 95% confidence interval (CI) 0.43-1.24; P = 0.25]. In cohort I, ORR was 38.3% (95% CI 24.40-52.20) for cobimetinib/paclitaxel and 20.9% (95% CI 8.77-33.09) for placebo/paclitaxel; ORRs in cohorts II and III were 34.4% (95% CI 18.57-53.19) and 29.0% (95% CI 14.22-48.04), respectively. Diarrhea was the most common grade ≥3 adverse events across all cohorts. CONCLUSIONS: Cobimetinib added to paclitaxel did not lead to a statistically significant increase in PFS or ORR, although a nonsignificant trend toward a numerical increase was observed. Cobimetinib plus atezolizumab and a taxane did not appear to increase ORR. This demonstrates the potential activity of a combinatorial MEK inhibitor, chemotherapy, and immunotherapy in this difficult-to-treat population.
引用
- Brufsky A, Kim SB, Zvirbule Ž, et al. A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis. Ann Oncol. 2021. PMID: 33539944. doi:10.1016/j.annonc.2021.01.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。